NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patientsSunny Malhotra, Manuel Comabella, Juan Carlos Triviño et al.|Brain|2020Cited by 136
Neurofilament light chain level is a weak risk factor for the development of MSGeorgina Arrambide, Mar Tintoré, Carmen Espejo et al.|Neurology|2016Cited by 108
Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosisLaura Calvo‐Barreiro, Carmen Espejo, Herena Eixarch et al.|Autoimmunity Reviews|2017Cited by 95
Immunosenescence in multiple sclerosis: the identification of new therapeutic targetsMaría Dema, Carmen Espejo, Herena Eixarch et al.|Autoimmunity Reviews|2021Cited by 94
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune EncephalomyelitisHerena Eixarch, Carmen Espejo|Neurotherapeutics|2020Cited by 12